Bacterial Conjunctivitis - Pipeline Review, H2 2016

Date: September 30, 2016
Pages: 42
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: BCFA8E949D6EN
Leaflet:

Download PDF Leaflet

Bacterial Conjunctivitis - Pipeline Review, H2 2016
Bacterial Conjunctivitis - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bacterial Conjunctivitis - Pipeline Review, H2 2016, provides an overview of the Bacterial Conjunctivitis (Ophthalmology) pipeline landscape.

Bacterial conjunctivitis is an inflammation of the conjunctiva caused by pathogenic bacteria. Bacterial conjunctivitis is usually caused by Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus sp, or, less commonly, Chlamydia trachomatis. Symptoms include redness in the white of the eye or inner eyelid, itchy eyes, blurred vision, increased sensitivity to light and burning eyes. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bacterial Conjunctivitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Bacterial Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bacterial Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Bacterial Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 2, 2 and 1 respectively for Bacterial Conjunctivitis.

Bacterial Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bacterial Conjunctivitis (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Bacterial Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bacterial Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bacterial Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bacterial Conjunctivitis (Ophthalmology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bacterial Conjunctivitis (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bacterial Conjunctivitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Bacterial Conjunctivitis Overview
Therapeutics Development
Pipeline Products for Bacterial Conjunctivitis - Overview
Bacterial Conjunctivitis - Therapeutics under Development by Companies
Bacterial Conjunctivitis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Bacterial Conjunctivitis - Products under Development by Companies
Bacterial Conjunctivitis - Companies Involved in Therapeutics Development
InSite Vision Incorporated
NovaBay Pharmaceuticals, Inc.
Shire Plc
Bacterial Conjunctivitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
auriclosene - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
azithromycin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ISV-405 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHP-640 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vancomycin hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bacterial Conjunctivitis - Dormant Projects
Bacterial Conjunctivitis - Product Development Milestones
Featured News & Press Releases
Jun 17, 2015: Manhattan U.S. Attorney Settles Civil Fraud Claims Against Inspire Pharmaceuticals For Its Misleading Marketing Designed To Cause Prescriptions Of Azasite For Non-Fda Approved Uses
Mar 17, 2015: InSite Vision Announces Settlement of Patent Infringement Lawsuit Against Mylan Pharmaceutical
Oct 03, 2013: Lupin launches Generic ZYMAXID Ophthalmic solution in the US
Aug 28, 2013: Lupin Receives FDA Approval For Gatifloxacin Eye Drops
Jul 01, 2013: Lupin Gets FDA Tentative Approval For Gatifloxacin Eye Drops
Jun 17, 2013: InSite Vision Announces Joint Patent Infringement Lawsuit With Merck Against Mylan Pharma
Mar 26, 2013: InSite Vision Wins Appeal Of Patent Interference Litigation Against University Of California, San Francisco
Jan 05, 2012: University Of California, San Francisco Files Appeal Of USPTO Judgment In Favor Of InSite Vision
Nov 28, 2011: InSite Vision Wins Patent Interference Litigation Against University Of California, San Francisco
Dec 17, 2009: NovaBay To Receive Increase In Funding And Support From Alcon
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 42

LIST OF TABLES

Number of Products under Development for Bacterial Conjunctivitis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Bacterial Conjunctivitis - Pipeline by InSite Vision Incorporated, H2 2016
Bacterial Conjunctivitis - Pipeline by NovaBay Pharmaceuticals, Inc., H2 2016
Bacterial Conjunctivitis - Pipeline by Shire Plc, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Bacterial Conjunctivitis - Dormant Projects, H2 2016 36

LIST OF FIGURES

Number of Products under Development for Bacterial Conjunctivitis, H2 2016
Number of Products under Development by Companies, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Bacterial Conjunctivitis - Pipeline Review, H1 2016 US$ 1,700.00 Apr, 2016 · 61 pages
Bacterial Vaginosis - Pipeline Review, H2 2016 US$ 2,000.00 Jul, 2016 · 61 pages
Bacterial Vaginosis - Pipeline Review, H1 2016 US$ 1,700.00 Feb, 2016 · 55 pages
Bacterial Pneumonia - Pipeline Review, H2 2014 US$ 1,500.00 Aug, 2014 · 55 pages

Ask Your Question

Bacterial Conjunctivitis - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: